Please login to the form below

Not currently logged in
Email:
Password:

Jacques Dumas joins Nosopharm scientific advisory board

French biotech's appointments also include Dominique Breilh

Nosopharm has appointed Jacques Dumas and three others to its scientific advisory board to strengthen its preclinical development programme.

Dumas, who has over 20 years of experience of antibiotic R&D, has previously held positions as chief scientific officer at Idenix Pharmaceuticals and VP and head of strategy for AstraZeneca infectious diseases unit.

He is joined on Nosopharm's scientific advisory board by Dominique Breilh, Jean-Michel Molina and Patrice Nordmann.

Dominique Breilh runs the pharmacokinetics and clinical pharmacy laboratory at the University of Bordeaux, France; Jean-Michel Molina is professor of infectious diseases at the University of Paris Diderot; and Patrice Nordmann is professor and director of the molecular microbiology unit at Switzerland's University of Fribourg.

French biotech company Nosopharm, which focus on anti-infective research, said the four appointments reflect a new phase of development for Odilorhabdins, a novel class of antibiotics it is developing.

Philippe Villain-Guillot, CEO of Nosopharm, said: “Dominique Breilh, Jacques Dumas, Jean-Michel Molina and Patrice Nordmann have internationally renowned skills and knowledge, which is a major asset for Nosopharm.

“Their appointments reflect our desire to ramp up our development. Our aim is to run phase I clinical trials starting in 2017 to evaluate a first-generation Odilorhabdin derived from out NOSO-95 molecule.”

19th November 2014

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
CSafe Global

CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...

Latest intelligence

How Far Do You Want To Go?
Join OPEN Health's virtual careers event on Tuesday 10th November, 15:00–17:00 GMT and discover where a career in medical communications could take you…...
"Fishbowl" Web Meeting for Internal POA Discussions: a Customer Story
Learn how our client successfully carried out a set of three virtual plan of action (POA) discussions, including one internal “Fishbowl” web meeting....
Whats the difference between patient engagement and patient experience?
We all talk a lot about patient engagement and patient experience. And sometimes, these terms are used interchangeably across the industry. But while they’re both important, they’re not the same....

Infographics